Skip to content

The impact and mechanism of circadian rhythm in neurology on acute cognitive function

The impact and mechanism of circadian rhythm in neurology on acute cognitive function

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099709
Enrollment
Unknown
Registered
2025-03-27
Start date
2024-01-15
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

experimental group:At night, there are 7 hours of wakefulness time, from 24:00 the previous day to 7:00 the next morning, and the working state is continuously awake
control group:Normal circadian rhythm for three consecutive days

Sponsors

Sanya Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years old, regardless of gender, healthy adult; 2. The circadian rhythm is reversed (there are 7 hours of wakefulness at night, that is, from 24:00 the previous day to 7:00 am the next day, continuous wakefulness work state); 3. The total score of Pittsburgh sleep quality index (PSQI) is <= 5 points; 4. No smoking or alcohol addiction or other substance abuse, no habit of drinking tea, coffee and other beverages; 5. Understand the entire research content, voluntarily participate in the experiment and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Existence of any form of sleep disorders and mental illness related sleep disorders, such as insomnia, depression, anxiety disorders, schizophrenia, and other mental illnesses; 2. Existence of other neurological and psychiatric disorders; 3. The presence of any organic or functional diseases, such as digestive system diseases, cardiovascular and cerebrovascular diseases, endocrine and metabolic diseases, and other chronic inflammatory diseases; 4. Refusing to accept urine retention and venous blood collection; 5. Pregnant, lactating, or menstruating women;

Design outcomes

Primary

MeasureTime frame
melatonin;Melatonin receptor;AQP4;LRP1;Aß40;Aß42;p-tau181;p-tau217;p-tau231;Trem2;AD7C-NTP;

Countries

China

Contacts

Public ContactWang Gaiqing

Sanya Central Hospital

wanggq08@163.com+86 152 8981 7816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026